What is NAD+ and why is it so central to cell health?
In every cell of the body, a reaction chain is constantly running, without which muscles could not contract, neurons could not fire, and no tissue could repair itself. At the center is a molecule most people have never heard of: NAD+, short for nicotinamide adenine dinucleotide.
NAD+ is not a vitamin or a supplement but an endogenous coenzyme that performs two fundamental roles. First, it functions as an electron carrier in the respiratory chain: in mitochondria, NAD+ accepts electrons (and is converted to NADH) to generate ATP in the electron transport chain, the cell’s universal energy currency. [1]
Secondly, NAD+ is an essential substrate for sirtuins (SIRT1–SIRT7), which regulate gene expression, stress response, and mitochondrial function as NAD+-dependent deacetylases. NAD+ is equally essential for PARP enzymes, which detect and repair damaged DNA. [4]
Why does NAD+ decrease with age, and what are the consequences?
An adult in their mid-60s still has about half the NAD+ level in many tissues that they had at age 20. [2] This decline has several well-understood causes: increased consumption by DNA repair enzymes (PARP-1) due to accumulating cell damage, increased activity of CD38, an NAD+-degrading enzyme in the immune system [3], and declining efficiency of the salvage pathway.
What this means in practice: less sirtuin activity (worse stress response and repair), less ATP production in mitochondria, and slower DNA repair. These three processes are closely linked to what we perceive as aging: declining muscle strength, poorer recovery, reduced cognitive performance. [4]
The three NAD+ precursors: NMN, NR, and NMNH
Those who want to increase NAD+ levels face a biochemical challenge: NAD+ itself as a supplement is not very effective because it hardly penetrates the cell membrane. Research therefore focuses on precursors, i.e., precursors that are taken up into the cell and converted there into NAD+.
| Feature | NMN | NR | NMNH |
|---|---|---|---|
| Full name | Nicotinamide mononucleotide | Nicotinamide riboside | Reduced NMN |
| Stage in NAD+ metabolism | Direct precursor (1 step via NMNAT) | Precursor (2 steps: NR → NMN → NAD+) | Direct precursor, already reduced |
| Human studies (RCT) | Yes, several (n up to 80) | Yes, several (n up to 60) | Very limited (early phase) |
| Direct comparison NMN vs. NR | NAD+ increase comparable to NR (Christen et al. 2026, Nat Metab) | NAD+ increase comparable to NMN (Christen et al. 2026, Nat Metab) | No direct comparison yet |
| Mechanism of action (new 2026) | Increase via Preiss-Handler pathway through gut flora conversion to NA | Increase via Preiss-Handler pathway through gut flora conversion to NA | Not yet clarified |
| Typical dose (studies) | 300–900 mg/day | 250–1,000 mg/day | 100–300 mg/day (exploratory) |
| Bioavailability | Well documented, orally active | Well documented, orally active | Very good (reduced form, preclinical) |
| NAD+ increase in blood | Significant, dose-dependent (Yi et al. 2023, GeroScience) | Significant (Trammell et al. 2016, Nat Commun) | Significant (Liao et al. 2021, preclinical) |
| Particular strength | Broad study base: muscle, energy metabolism | Mitochondria skeletal muscle, older adults | Potentially more efficient absorption |
| Youngle product available | Yes (powder & capsules) | Yes (powder & capsules) | Yes (powder) |
Table: Comparison of the three main NAD+ precursors (as of March 2026). New data from Christen et al. 2026 (Nature Metabolism) integrated.
NMN is the most direct precursor of NAD+ and the most widely studied substance in this group. Several controlled human studies demonstrate dose-dependent NAD+ increases as well as improvements in insulin sensitivity and mobility. A complete classification of the studies, dosage recommendations, and quality criteria can be found in the Pillar article on NMN. [5][6]
NR (Nicotinamide Riboside) is first converted to NMN in the body, thus reaching the same NAD+ synthesis pathway. Its bioavailability is well documented, and NR has particularly strong skeletal muscle data from direct tissue measurements. Everything essential about effects, bioavailability, and comparison with NMN is summarized in the NR Pillar. [8][9]
The key finding for this comparison: Christen et al. showed in 2026 in Nature Metabolism in the first direct human comparison that NMN and NR increase circulating NAD+ levels comparably after 14 days. Mechanistically, this happens for both substances through gut flora conversion to nicotinic acid and subsequent NAD+ synthesis via the Preiss-Handler pathway, not as long assumed via the direct intracellular route. [7]
NMNH (reduced NMN) is the newest of the three substances in clinical research. Preclinical data show a faster and more pronounced NAD+ increase than NMN with good tolerability. However, full RCT clinical human studies are still lacking. NMNH is therefore more relevant for people who actively follow developments in NAD+ research.
What clinical studies show and what they don’t
What is well supported across substances: NAD+ precursors measurably and reproducibly increase NAD+ levels in the blood. This is the most robust finding in the entire literature. Beyond that, there are data for NMN and NR on specific clinical endpoints such as insulin sensitivity, muscle function, and mitochondrial activity, but only in small samples and short observation periods.
What is not proven: a direct effect on lifespan, dementia prevention, or cardiovascular outcomes. These goals are biologically plausible but not demonstrated in humans. The detailed study assessment can be found in the respective pillar articles on NMN and NR.
State of evidence
An honest assessment of the current research status, including the new direct comparison study from 2026:
| Level of evidence | Study type | Finding | Assessment |
|---|---|---|---|
| Human studies | RCT (n=80) | 300/600/900 mg NMN significantly increase blood NAD+ after 60 days. Gait test improvement in all NMN groups vs. placebo. (Yi et al. 2023, GeroScience) | 🟢 Strong, placebo-controlled, dose-dependent |
| Human studies | RCT (n=65, 4-arm) | NMN and NR increase circulating NAD+ comparably after 14 days. First direct comparison NMN vs. NR in humans. Mechanism: Preiss-Handler via gut flora. (Christen et al. 2026, Nat Metab) | 🟢 Strong, so far only head-to-head comparison |
| Human studies | RCT (n=25) | 250 mg NMN improves insulin sensitivity and muscle metabolism in premenopausal women (Yoshino et al. 2021, Science) | 🟢 Strong, high-impact publication, metabolic relevance |
| Human studies | RCT (n=48) | NR improves mitochondrial function in skeletal muscles of older adults, anti-inflammatory gene expression profile (Elhassan et al. 2019, Cell Reports) | 🟢 Strong, direct tissue data |
| Human studies | RCT (n=30) | NR increases blood NAD+ dose-dependently. First human bioavailability study (Trammell et al. 2016, Nat Commun) | 🟢 Strong, basis of oral bioavailability |
| Human studies | Open-label (n=10) | NMN safe and well tolerated, dose-dependent NAD+ increase (Irie et al. 2020, Endocrine J) | 🟡 Moderate, no control group |
| Animal model | Mouse study | NMN increases NAD+, improves energy metabolism, muscle strength, and body weight in aging mice (Mills et al. 2016, Cell Metab) | 🟡 Limited, transferability unclear |
| Mechanistic | Biochemistry | NAD+ activates sirtuin enzymes (SIRT1, SIRT3), which regulate DNA repair and mitochondrial function; PARP and CD38 consumption explain age-related decline | 🔵 Basis, explains mechanism of action |
| Gaps | Missing data | No long-term studies >6 months. No direct longevity evidence in humans. Effect on cognitive function and heart health in humans not proven. | 🔴 Open, further research needed |
🟢 Strong evidence (RCT in humans) · 🟡 Moderate evidence · 🔵 Mechanistic evidence · 🔴 Missing data
NAD+ supplementation and methylation: Why TMG might be relevant
NMN and NR are metabolized in the body. This produces, among other things, nicotinamide, which must be methylated to be excreted. This step consumes S-adenosylmethionine (SAM), the cell’s universal methyl group donor. TMG (trimethylglycine) is an affordable methyl group donor that addresses this potential bottleneck.
Direct clinical evidence that TMG improves the NAD+ effect or prevents a deficiency is still lacking. The combination is mechanistically justified and common in the longevity community but is not considered an established standard. A complete introduction to methylation, homocysteine, TMG dosage, and the data situation can be found in the TMG article.
Who benefits from NAD+ precursors?
The strongest evidence is for people aged 40 and above, where the NAD+ decline is already measurable and manifests in reduced energy levels, muscle strength, or recovery. The data show particular relevance for people with metabolic risk factors such as overweight or prediabetes. Yoshino et al. demonstrated specific improvements in insulin sensitivity in a Science study. Active people and athletes also find concrete indications in the data for muscle recovery and endurance capacity.
The benefit is less clear for people under 35 with good baseline health, whose NAD+ levels are still sufficiently high.
Dosage, timing, and practical notes
Both substances were taken daily and in the morning in clinical studies. The dosage ranges differ between NMN and NR, and the data situation is also substance-specific. A complete evaluation of dosage studies on NMN, including dose-response data and comparison of different age groups, can be found in the NMN dosing article. The substance-specific dosage recommendations for NR are summarized in the NR-Pillar.
Quality criteria apply equally to both substances: laboratory-confirmed purity, current analysis certificates from independent labs, and light-protected storage. NMN has GRAS status in the USA; NR has Novel Food approval in the EU.
